At the end of the latest market close, Novavax Inc. (NVAX) was valued at $236.93. In that particular session, Stock kicked-off at the price of $239.50 while reaching the peak value of $249.45 and lowest value recorded on the day was $235.11. The stock current value is $205.16.
Recently in News on May 3, 2021, Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine. – PREVENT-19 clinical trial expanded to assess the efficacy, safety and immunogenicity of NVX-CoV2373 for the prevention of COVID-19 in up to 3,000 12-17-year-old adolescents. You can read further details here
Novavax Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $331.68 on 02/09/21, with the lowest value was $109.01 for the same time period, recorded on 01/04/21.
Novavax Inc. (NVAX) full year performance was 1206.84%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Novavax Inc. shares are logging -38.15% during the 52-week period from high price, and 1150.21% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $16.41 and $331.68.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 3088048 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Novavax Inc. (NVAX) recorded performance in the market was 112.47%, having the revenues showcasing 7.24% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 17.54B, as it employees total of 791 workers.
Specialists analysis on Novavax Inc. (NVAX)
During the last month, 5 analysts gave the Novavax Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 187.69, with a change in the price was noted +91.04. In a similar fashion, Novavax Inc. posted a movement of +73.94% for the period of last 100 days, recording 4,088,565 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for NVAX is recording 0.75 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.58.
Trends and Technical analysis: Novavax Inc. (NVAX)
Raw Stochastic average of Novavax Inc. in the period of last 50 days is set at 51.46%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 46.87%. In the last 20 days, the company’s Stochastic %K was 63.37% and its Stochastic %D was recorded 73.06%.
Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 112.47%. Additionally, trading for the stock in the period of the last six months notably improved by 191.32%, alongside a boost of 1206.84% for the period of the last 12 months. The shares increased approximately by 14.12% in the 7-day charts and went down by 30.68% in the period of the last 30 days. Common stock shares were driven by 7.24% during last recorded quarter.